miR-146a promotes M2 macrophage polarization and accelerates diabetic wound healing by inhibiting the TLR4/NF-κB axis. 2022

Xuefeng Peng, and Fang He, and Yanling Mao, and Yihui Lin, and Jingwen Fang, and Yangchun Chen, and Zhichun Sun, and Yafen Zhuo, and Jianjia Jiang
Department of Endocrinology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, People's Republic of China.

We tried to unveil the clinical significance of miR-146a as a biomarker in M2 macrophage polarization in diabetic wound healing. Initially, we found reduced miR-146a in macrophages of diabetic patients. Next, dual-luciferase assay verified that toll-like receptor 4 (TLR4) was a target gene of miR-146 and was negatively regulated by miR-146. Moreover, after ectopic expression and depletion experiments of miR-146 and/or TLR4, lipopolysaccharide-induced inflammatory response of macrophages was detected. The results revealed that overexpression of miR-146a promoted the M2 macrophage polarization by suppressing the TLR4/nuclear factor-kappaB (NF-κB) axis, so as to enhance wound healing in diabetic ulcers. Further, mouse models with diabetic ulcers were established to investigate the effects of miR-146a on diabetic wound healing in vivo, which revealed that miR-146a promoted wound healing in diabetic ulcers by inhibiting the TLR4/NF-κB axis. In conclusion, we demonstrate that miR-146a can induce M2 macrophage polarization to enhance wound healing in diabetic ulcers by inhibiting the TLR4/NF-κB axis.

UI MeSH Term Description Entries
D008262 Macrophage Activation The process of altering the morphology and functional activity of macrophages so that they become avidly phagocytic. It is initiated by lymphokines, such as the macrophage activation factor (MAF) and the macrophage migration-inhibitory factor (MMIF), immune complexes, C3b, and various peptides, polysaccharides, and immunologic adjuvants. Activation, Macrophage,Activations, Macrophage,Macrophage Activations
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014456 Ulcer A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue. Ulcers
D014945 Wound Healing Restoration of integrity to traumatized tissue. Healing, Wound,Healings, Wound,Wound Healings
D016328 NF-kappa B Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA. Immunoglobulin Enhancer-Binding Protein,NF-kappa B Complex,Nuclear Factor kappa B,Transcription Factor NF-kB,kappa B Enhancer Binding Protein,Ig-EBP-1,NF-kB,NF-kappaB,Nuclear Factor-Kappab,Complex, NF-kappa B,Enhancer-Binding Protein, Immunoglobulin,Factor NF-kB, Transcription,Factor-Kappab, Nuclear,Ig EBP 1,Immunoglobulin Enhancer Binding Protein,NF kB,NF kappa B Complex,NF kappaB,NF-kB, Transcription Factor,Nuclear Factor Kappab,Transcription Factor NF kB
D048909 Diabetes Complications Conditions or pathological processes associated with the disease of diabetes mellitus. Due to the impaired control of BLOOD GLUCOSE level in diabetic patients, pathological processes develop in numerous tissues and organs including the EYE, the KIDNEY, the BLOOD VESSELS, and the NERVE TISSUE. Complications of Diabetes Mellitus,Diabetes-Related Complications,Diabetic Complications,Diabetes Complication,Diabetes Mellitus Complication,Diabetes Mellitus Complications,Diabetes Related Complications,Diabetes-Related Complication,Diabetic Complication
D051197 Toll-Like Receptor 4 A pattern recognition receptor that interacts with LYMPHOCYTE ANTIGEN 96 and LIPOPOLYSACCHARIDES. It mediates cellular responses to GRAM-NEGATIVE BACTERIA. TLR4 Receptor,Toll-4 Receptor,Receptor, TLR4,Toll 4 Receptor,Toll Like Receptor 4

Related Publications

Xuefeng Peng, and Fang He, and Yanling Mao, and Yihui Lin, and Jingwen Fang, and Yangchun Chen, and Zhichun Sun, and Yafen Zhuo, and Jianjia Jiang
January 2021, Frontiers in medicine,
Xuefeng Peng, and Fang He, and Yanling Mao, and Yihui Lin, and Jingwen Fang, and Yangchun Chen, and Zhichun Sun, and Yafen Zhuo, and Jianjia Jiang
January 2024, Molecular and cellular endocrinology,
Xuefeng Peng, and Fang He, and Yanling Mao, and Yihui Lin, and Jingwen Fang, and Yangchun Chen, and Zhichun Sun, and Yafen Zhuo, and Jianjia Jiang
January 2024, Molecular and cellular biochemistry,
Xuefeng Peng, and Fang He, and Yanling Mao, and Yihui Lin, and Jingwen Fang, and Yangchun Chen, and Zhichun Sun, and Yafen Zhuo, and Jianjia Jiang
December 2022, European journal of pharmacology,
Xuefeng Peng, and Fang He, and Yanling Mao, and Yihui Lin, and Jingwen Fang, and Yangchun Chen, and Zhichun Sun, and Yafen Zhuo, and Jianjia Jiang
May 2023, Heliyon,
Xuefeng Peng, and Fang He, and Yanling Mao, and Yihui Lin, and Jingwen Fang, and Yangchun Chen, and Zhichun Sun, and Yafen Zhuo, and Jianjia Jiang
December 2022, Pharmaceutical biology,
Xuefeng Peng, and Fang He, and Yanling Mao, and Yihui Lin, and Jingwen Fang, and Yangchun Chen, and Zhichun Sun, and Yafen Zhuo, and Jianjia Jiang
April 2022, Cell death discovery,
Xuefeng Peng, and Fang He, and Yanling Mao, and Yihui Lin, and Jingwen Fang, and Yangchun Chen, and Zhichun Sun, and Yafen Zhuo, and Jianjia Jiang
January 2024, International journal of biological sciences,
Xuefeng Peng, and Fang He, and Yanling Mao, and Yihui Lin, and Jingwen Fang, and Yangchun Chen, and Zhichun Sun, and Yafen Zhuo, and Jianjia Jiang
December 2021, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology,
Xuefeng Peng, and Fang He, and Yanling Mao, and Yihui Lin, and Jingwen Fang, and Yangchun Chen, and Zhichun Sun, and Yafen Zhuo, and Jianjia Jiang
March 2024, International journal of biological macromolecules,
Copied contents to your clipboard!